• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Supportive care in multiple myeloma: Current practices and advances.多发性骨髓瘤的支持性治疗:现状与进展。
Cancer Treat Res Commun. 2021;29:100476. doi: 10.1016/j.ctarc.2021.100476. Epub 2021 Oct 9.
2
Advances in supportive care for multiple myeloma.多发性骨髓瘤的支持性治疗进展。
J Natl Compr Canc Netw. 2014 Apr;12(4):502-11. doi: 10.6004/jnccn.2014.0055.
3
Supportive Care in Multiple Myeloma.多发性骨髓瘤的支持性护理。
Curr Hematol Malig Rep. 2020 Apr;15(2):56-61. doi: 10.1007/s11899-020-00570-9.
4
Supportive care in multiple myeloma.多发性骨髓瘤的支持性护理。
Clin Lymphoma Myeloma. 2006 Jul;7(1):42-50. doi: 10.3816/CLM.2006.n.038.
5
International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.国际骨髓瘤工作组关于不符合标准自体干细胞移植条件的骨髓瘤患者的管理、治疗和支持性护理的共识声明。
J Clin Oncol. 2014 Feb 20;32(6):587-600. doi: 10.1200/JCO.2013.48.7934. Epub 2014 Jan 13.
6
Guidelines for supportive care in multiple myeloma 2011.多发性骨髓瘤支持治疗指南 2011 年版
Br J Haematol. 2011 Jul;154(1):76-103. doi: 10.1111/j.1365-2141.2011.08574.x. Epub 2011 Apr 22.
7
Management of Myeloma Manifestations and Complications: The Cornerstone of Supportive Care: Recommendation of the Canadian Myeloma Research Group (formerly Myeloma Canada Research Network) Consensus Guideline Consortium.骨髓瘤表现与并发症的管理:支持性护理的基石:加拿大骨髓瘤研究小组(原加拿大骨髓瘤研究网络)共识指南联盟的建议
Clin Lymphoma Myeloma Leuk. 2022 Jan;22(1):e41-e56. doi: 10.1016/j.clml.2021.07.028. Epub 2021 Aug 1.
8
Underutilization of guideline-recommended supportive care among older adults with multiple myeloma in the United States.美国老年多发性骨髓瘤患者中指南推荐的支持性护理未得到充分利用。
Cancer. 2019 Nov 15;125(22):4084-4095. doi: 10.1002/cncr.32428. Epub 2019 Aug 5.
9
Symptoms and anxiety predict declining health-related quality of life in multiple myeloma: A prospective, multi-centre longitudinal study.症状和焦虑可预测多发性骨髓瘤患者健康相关生活质量的下降:一项前瞻性、多中心纵向研究。
Palliat Med. 2019 May;33(5):541-551. doi: 10.1177/0269216319833588.
10
[Current approaches to supportive care in multiple myeloma].[多发性骨髓瘤支持性护理的当前方法]
Srp Arh Celok Lek. 2011 Dec;139 Suppl 2:123-8. doi: 10.2298/sarh11s2123g.

引用本文的文献

1
Thromboprophylaxis in multiple myeloma.多发性骨髓瘤的血栓预防
Res Pract Thromb Haemost. 2025 Jan 16;9(1):102685. doi: 10.1016/j.rpth.2025.102685. eCollection 2025 Jan.
2
Frontline management of multiple myeloma patients: optimizing treatment for patients in the Gulf region.多发性骨髓瘤患者的一线管理:优化海湾地区患者的治疗
Clin Hematol Int. 2025 Feb 11;7(1):14-28. doi: 10.46989/001c.128113. eCollection 2025.
3
Recent advances in the treatment and prevention of peripheral neuropathy after multiple myeloma treatment.多发性骨髓瘤治疗后周围神经病变治疗与预防的最新进展
Ibrain. 2023 Sep 6;9(4):421-430. doi: 10.1002/ibra.12132. eCollection 2023 Winter.
4
Pain Management in Multiple Myeloma Patients: A Literature Review.多发性骨髓瘤患者的疼痛管理:文献综述
Cureus. 2024 Mar 11;16(3):e55975. doi: 10.7759/cureus.55975. eCollection 2024 Mar.
5
Practical management of disease-related manifestations and drug toxicities in patients with multiple myeloma.多发性骨髓瘤患者疾病相关表现及药物毒性的实际管理
Front Oncol. 2024 Mar 22;14:1282300. doi: 10.3389/fonc.2024.1282300. eCollection 2024.
6
Evolving progress in the management of malignant plasma cell disorders.恶性浆细胞疾病管理方面的进展演变
Cancer Treat Res Commun. 2022;32:100612. doi: 10.1016/j.ctarc.2022.100612. Epub 2022 Jul 19.

本文引用的文献

1
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis.比较新诊断多发性骨髓瘤患者接受硼替佐米、来那度胺、地塞米松(RVD)或卡非佐米、来那度胺、地塞米松(KRD)联合阿司匹林或利伐沙班预防静脉血栓栓塞症的发生率。
Br J Haematol. 2022 Jan;196(1):105-109. doi: 10.1111/bjh.17772. Epub 2021 Aug 15.
2
Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM).贝兰他单抗mafodotin 相关角膜事件的管理在复发或难治性多发性骨髓瘤(RRMM)患者中的应用。
Blood Cancer J. 2021 May 26;11(5):103. doi: 10.1038/s41408-021-00494-4.
3
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study.IMPEDE VTE 评分对多发性骨髓瘤静脉血栓栓塞症预测的验证:一项回顾性队列研究。
Br J Haematol. 2021 Jun;193(6):1213-1219. doi: 10.1111/bjh.17505. Epub 2021 May 17.
4
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma.多发性骨髓瘤患者对严重急性呼吸综合征冠状病毒2首次疫苗接种的反应。
Lancet Haematol. 2021 Jun;8(6):e389-e392. doi: 10.1016/S2352-3026(21)00110-1. Epub 2021 Apr 19.
5
Efficacy of Intravenous Immunoglobulin for Preventing Infections in Patients with Multiple Myeloma.静脉注射免疫球蛋白对预防多发性骨髓瘤患者感染的疗效
Clin Lymphoma Myeloma Leuk. 2021 May;21(5):e470-e476. doi: 10.1016/j.clml.2020.12.026. Epub 2021 Feb 7.
6
Cancer Statistics, 2021.癌症统计数据,2021.
CA Cancer J Clin. 2021 Jan;71(1):7-33. doi: 10.3322/caac.21654. Epub 2021 Jan 12.
7
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set.与 COVID-19 多发性骨髓瘤患者结局相关的临床特征:国际骨髓瘤学会数据集的初步结果。
Blood. 2020 Dec 24;136(26):3033-3040. doi: 10.1182/blood.2020008150.
8
Physical activity is associated with less comorbidity, better treatment tolerance and improved response in patients with multiple myeloma undergoing stem cell transplantation.身体活动与多发性骨髓瘤患者接受干细胞移植后的合并症减少、更好的治疗耐受性和改善的反应相关。
J Geriatr Oncol. 2021 May;12(4):521-530. doi: 10.1016/j.jgo.2020.11.003. Epub 2020 Nov 20.
9
Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.单药贝兰他单抗mafodotin 治疗复发/难治性多发性骨髓瘤:关键性 DREAMM-2 研究中冻干制剂队列的分析。
Blood Cancer J. 2020 Oct 23;10(10):106. doi: 10.1038/s41408-020-00369-0.
10
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.卡非佐米或硼替佐米联合来那度胺和地塞米松治疗无即刻自体干细胞移植意向的新诊断多发性骨髓瘤患者(ENDURANCE):一项多中心、开放标签、3 期、随机、对照临床试验。
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.

多发性骨髓瘤的支持性治疗:现状与进展。

Supportive care in multiple myeloma: Current practices and advances.

机构信息

Division of Hematology, Mayo Clinic Rochester, United States.

Division of Hematology, Mayo Clinic Rochester, United States.

出版信息

Cancer Treat Res Commun. 2021;29:100476. doi: 10.1016/j.ctarc.2021.100476. Epub 2021 Oct 9.

DOI:10.1016/j.ctarc.2021.100476
PMID:34653748
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8688260/
Abstract

Supportive care in multiple myeloma (MM) can have a major impact on quality of life and the survival outcomes of MM patients. In this review, we will focus on disease and treatment related toxicities experienced by MM patients and what are the best approaches to date to help mitigate the effects. We will specifically focus on a practical approach to managing bone disease, thrombosis, infection risk, peripheral neuropathy, dermatologic complications, gastrointestinal and ocular toxicities, and fatigue in MM.

摘要

在多发性骨髓瘤(MM)中,支持性护理可以对患者的生活质量和生存结果产生重大影响。在这篇综述中,我们将重点关注 MM 患者经历的疾病和治疗相关毒性,以及迄今为止帮助减轻这些影响的最佳方法。我们将特别关注管理 MM 患者骨骼疾病、血栓形成、感染风险、周围神经病、皮肤并发症、胃肠道和眼部毒性以及疲劳的实用方法。